Citations

Clear

69 citation(s) found for "Feagan, Brian".

Editorial: validating reliability of the eosinophilic oesophagitis histological scoring system (EOE‐HSS)—an important first step. Authors’ reply
Pai, Rish K. , Bredenoord, Albert J. , Feagan, Brian G. , Jairath, Vipul , Jairath, Vipul , Jairath, Vipul , Feagan, B G , Jairath, V , Jairath, V , Jairath, Vipul

Mayo Clinic

Alimentary Pharmacology & Therapeutics | May 31, 2018 | Volume: 47 | Issue: 12 | Pages: 1714-1715

10.1111/apt.14658 | PMID 29878503 Get It

Linked contentThis article is linked to Warners et al and Conner and Kirsch papers. To view these articles https://doi.org/10.1111/apt.14559 and https://doi.org/10.1111/apt.14633.
Systematic review with meta‐analysis: endoscopic and histologic placebo rates in induction and maintenance trials of ulcerative colitis
Ma, Christopher , Guizzetti, Leonardo , Pai, Rish K. , Parker, Claire E. , Nguyen, Tran M , Khanna, Reena , Casteele, Niels Vande , D’Haens, Geert , Sandborn, William J. , Feagan, Brian G. , Ma, C , Guizzetti, L , Fedorak, R N , Pai, R K , Vande Casteele, N , D'Haens, G , Sandborn, W J , Feagan, B G , Jairath, V , Panaccione, Remo , Fedorak, Richard N. , Jairath, Vipul

Mayo Clinic

Alimentary Pharmacology & Therapeutics | April 26, 2018 | Volume: 47 | Issue: 12 | Pages: 1578-1596

10.1111/apt.14672 | PMID 29696670 Get It

Summary Background Regulatory requirements for claims of mucosal healing in ulcerative colitis ( UC ) will require demonstration of both endoscopic and histologic healing. Quantifying these rates is essential for future drug development. Aims To meta‐analyse endoscopic and histologic placebo response and remission rates in UC randomised controlled trials ( RCT s) and identify factors influencing these rates. Methods MEDLINE , EMBASE and the Cochrane Library were searched from inception to March 2017 for placebo‐controlled trials of pharmacological interventions for UC . Endoscopic and histologic placebo rates were pooled by random effects. Mixed effects univariable and multivariable meta‐regression was used to evaluate the influence of patient, intervention and trial‐related study‐level covariates on these rates. Results Fifty‐six induction (placebo n = 4171) and 8 maintenance trials (placebo n = 1011) were included. Pooled placebo endoscopic remission and response rates for induction trials were 23% [95 confidence interval ( CI ) 19‐28%] and 35% [95% CI 27‐42%] respectively, and 20% [95% CI 16‐24%] for maintenance of remission. The pooled histologic placebo remission rate was 14% [95% CI 8‐22%] for induction trials. High heterogeneity was observed for all outcomes ( I 2 56.2%‐88.3%). On multivariable meta‐regression, central endoscopy reading was associated with significantly lower endoscopic placebo remission rates (16% vs 25%; OR = 0.52, [95% CI 0.29‐0.92], P = 0.03). On univariable meta‐regression, higher histologic placebo remission was associated with concomitant corticosteroids ( OR = 1.17 [95% CI 1.08‐1.26], P < 0.0001, per 10% increase in corticosteroid use). Conclusions Placebo endoscopic and histologic rates range from 14% to 35% in UC RCT s but are highly heterogeneous. Outcome standardisation may reduce heterogeneity and is needed in this field.
A102 TOLERABILITY OF USTEKINUMAB IN INDUCTION AND MAINTENANCE FOR THE TREATMENT OF CROHN’S DISEASE
Jacobstein, D, Gasink, Christopher , Sloan, S , Feagan, Brian G. , Loftus, Edward V. , Sattin, Bernie D. , Jacobstein, D, Colombel, Jean‐Frédéric

Mayo Clinic

Journal of the Canadian Association of Gastroenterology | March 1, 2018 | Volume: 1 | Issue: suppl_2 | Pages: 153-154

10.1093/jcag/gwy009.102 Get It

Histologic scoring indices for evaluation of disease activity in Crohn’s disease
Novak, Gregor , Parker, Claire E. , Pai, Rish K. , MacDonald, John K, Feagan, Brian G. , Sandborn, William J. , D’Haens, Geert , Khanna, Reena , Jairath, Vipul

Mayo Clinic

Cochrane Database of Systematic Reviews | July 21, 2017 | Volume: 2017 | Issue: 7 | Pages: No page available

10.1002/14651858.cd012351.pub2 | PMID 28731502 Get It

Development of an index to define overall disease severity in IBD
Whitman, Cynthia B. , Spiegel, Brennan , Feagan, Brian G. , Loftus, Edward V. , D’Haens, Geert , Bernstein, Çharles N. , Gearry, Richard B. , Mantzaris, Gerassimos J. , Sartor, Balfour R., Silverberg, Mark S. , Riddell, Robert H. , O’Morain, Colm, Lakatos, Péter L. , Halfvarson, Jonas , Reinisch, Walter, Rogler, Gerhard , Kruis, Wolfgang , Tysk, Curt , Danese, Silvio , Sandborn, William J. , Gasché, Christoph , Pallone, Francesco, Travis, Simon , Peyrin‐Biroulet, Laurent , Siegel, Corey A , Sands, Bruce E , Panaccione, Remo , Bernstein, Charles Noah , Ng, Siew C. , Κoutroubakis, Ioannis E. , McGovern, Dermot , Halfvarson, Jonas , Schreiber, Stefan , Griffiths, Anne Marie , Moum, Bjørn Allan , Panés, Julián , Colombel, Jean‐Frédéric , Hanauer, Stephen B. , Loftus, Edward V , Danese, Silvio , Peyrin-Biroulet, Laurent , Spiegel, Brennan , Lakatos, Peter L

Mayo Clinic

Gut | October 25, 2016 | Volume: 67 | Issue: 2 | Pages: 244-254

10.1136/gutjnl-2016-312648 | PMID 27780886 Get It

Background and aim Disease activity for Crohn's disease (CD) and UC is typically defined based on symptoms at a moment in time, and ignores the long-term burden of disease. The aims of this study were to select the attributes determining overall disease severity, to rank the importance of and to score these individual attributes for both CD and UC. Methods Using a modified Delphi panel, 14 members of the International Organization for the Study of Inflammatory Bowel Diseases (IOIBD) selected the most important attributes related to IBD. Eighteen IOIBD members then completed a statistical exercise (conjoint analysis) to create a relative ranking of these attributes. Adjusted utilities were developed by creating proportions for each level within an attribute. Results For CD, 15.8% of overall disease severity was attributed to the presence of mucosal lesions, 10.9% to history of a fistula, 9.7% to history of abscess and 7.4% to history of intestinal resection. For UC, 18.1% of overall disease severity was attributed to mucosal lesions, followed by 14.0% for impact on daily activities, 11.2% C reactive protein and 10.1% for prior experience with biologics. Overall disease severity indices were created on a 100-point scale by applying each attribute's average importance to the adjusted utilities. Conclusions Based on specialist opinion, overall CD severity was associated more with intestinal damage, in contrast to overall UC disease severity, which was more dependent on symptoms and impact on daily life. Once validated, disease severity indices may provide a useful tool for consistent assessment of overall disease severity in patients with IBD.
Randomised clinical trial: a phase 1, dose‐ranging study of the anti‐matrix metalloproteinase‐9 monoclonal antibody GS‐5745 versus placebo for ulcerative colitis
Sandborn, William J. , Bhandari, Bal Raj, Fogel, Ronald, Onken, Jane E., Yen, Eugene F. , Zhao, Xin , Jiang, Zhaoshi , Ge, Dongliang , Xin, Y., Ye, Z., French, Dorothy, Silverman, Jeffrey A., Kanwar, Bittoo, Subramanian, G. Mani , McHutchison, John G., Lee, S. D., Shackelton, Lisa M. , Pai, Rish K. , Levesque, Barrett G., Feagan, Brian G. , Xin, Y.

Mayo Clinic

Alimentary Pharmacology & Therapeutics | May 25, 2016 | Volume: 44 | Issue: 2 | Pages: 157-169

10.1111/apt.13653 | PMID 27218676 Get It

SummaryBackgroundMatrix metalloproteinase‐9 is a proteolytic enzyme whose expression is increased in ulcerative colitis.AimTo evaluate the safety and efficacy of GS‐5745, a fully humanised anti‐matrix metalloproteinase‐9 monoclonal antibody, in moderately‐to‐severely active ulcerative colitis.MethodsWe randomised 74 patients with ulcerative colitis to treatment with single or multiple ascending intravenous or subcutaneous doses of GS‐5745 or placebo. Multiple‐dose cohorts received either IV infusions (0.3, 1.0, 2.5 or 5.0 mg/kg GS‐5745 or placebo) every 2 weeks (three total IV infusions) or five weekly SC injections (150 mg GS‐5745 or placebo). The primary outcomes were the safety, tolerability and pharmacokinetics of escalating single and multiple doses of GS‐5745. Exploratory analyses in the multiple‐dose cohorts included clinical response (≥3 points or 30% decrease from baseline in Mayo Clinic score and ≥1 point decrease in the rectal bleeding subscore or a rectal bleeding subscore ≤1) and clinical remission (a complete Mayo Clinic score ≤2 with no subscore >1) at Day 36. Biological effects associated with a clinical response to GS‐5745 were explored using histological and molecular approaches.ResultsTwenty‐three of the 42 patients (55%) receiving multiple doses of GS‐5745 had adverse events, compared with 5/8 patients (63%) receiving placebo. GS‐5745 showed target‐mediated drug disposition, approximately dose‐proportional increases in maximum plasma concentration and more than dose‐proportional increases in the area under the plasma drug concentration‐time curve. Clinical response occurred in 18/42 patients (43%) receiving GS‐5745 compared with 1/8 patients (13%) receiving placebo. Clinical remission occurred in 6/42 patients (14%) receiving GS‐5745 and 0/8 (0%) receiving placebo. Patients with a clinical response to GS‐5745 had reductions in matrix metalloproteinase‐9 tissue levels (mean 48.9% decrease from baseline compared with a mean 18.5% increase in nonresponders, P = 0.008) significant improvements in histopathology scores (confirmed with three separate histological disease activity indices), as well as changes in colonic gene expression that were consistent with reduced inflammation.ConclusionThis phase 1 trial provides preliminary evidence for the safety and therapeutic potential of GS‐5745 in the treatment of ulcerative colitis.
The safety of vedolizumab for ulcerative colitis and Crohn's disease
Rutgeerts, Paul, Sandborn, William J. , Danese, Silvio , D’Haens, Geert , Loftus, Edward V. , Sankoh, Serap, Fox, Irving H., Parikh, Asit, Milch, Catherine , Abhyankar, Brihad, Feagan, Brian G. , Colombel, Jean‐Frédéric , Sands, Bruce E , Panaccione, Remo , Loftus, Edward V , Danese, Silvio

Mayo Clinic

Gut | April 13, 2016 | Volume: 66 | Issue: 5 | Pages: 839-851

10.1136/gutjnl-2015-311079 | PMID 26893500 Get It

Objective Vedolizumab is a gut-selective antibody to α 4 β 7 integrin for the treatment of ulcerative colitis (UC) and Crohn's disease (CD). We report an integrated summary of the safety of vedolizumab. Design Safety data (May 2009–June 2013) from six trials of vedolizumab were integrated. Adverse events were evaluated in patients who received ≥1 dose of vedolizumab or placebo and were reported as exposure-adjusted incidence rates as the number of patients experiencing the event per 100 person-years (PYs) of exposure. Predictors of serious infection were assessed using a Cox proportional hazards model. Results In total, 2830 patients had 4811 PYs of vedolizumab exposure (median exposure range, 1–1977 days). No increased risk of any infection or serious infection was associated with vedolizumab exposure. Serious clostridial infections, sepsis and tuberculosis were reported infrequently (≤0.6% of patients). No cases of progressive multifocal leucoencephalopathy were observed. Independent risk factors for serious infection in UC were prior failure of a tumour necrosis factor α antagonist (HR, 1.99; 95% CIs 1.16 to 3.42; p=0.0122) and narcotic analgesic use (HR, 2.68; 95% CI 1.57 to 4.58; p=0.0003), and in CD were younger age (HR, 0.97; 95% CI 0.95 to 0.98; p<0.0001), corticosteroid (HR, 1.88; 95% CI 1.35 to 2.63; p=0.0002) or narcotic analgesic use (HR, 2.72; 95% CI 1.90 to 3.89; p<0.0001). Investigator-defined infusion-related reactions were reported for ≤5% of patients in each study. Eighteen vedolizumab-exposed patients (<1%) were diagnosed with a malignancy. Conclusions Vedolizumab has a favourable safety profile with low incidence rates of serious infections, infusion-related reactions and malignancies over an extended treatment period. Trial registration number NCT01177228, NCT00619489 , NCT00783718 , NCT00783692 , NCT01224171 , NCT00790933 .
MRI scoring indices for evaluation of disease activity and severity in Crohn’s disease
Dulai, Parambir S. , Singh, Siddharth , Cesarini, Monica , Nelson, Sigrid, Feagan, Brian G. , Ordás, Íngrid , Sandborn, William J. , Santillan, Cynthia , D’Haens, Geert , Stoker, Jaap , MacDonald, John K, Levesque, Barrett G., Bouguen, Guillaume , Peyrin‐Biroulet, Laurent , Rimola, Jordi , Panés, Julián , Zou, Guangyong , Stoker, Jaap , Ordás, Ingrid

Mayo Clinic

Cochrane Database of Systematic Reviews | April 10, 2015 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/14651858.cd011630 Get It

Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double blind, placebo controlled, dose ranging trial
Assche, Gert Van , Sandborn, William J. , Feagan, Brian G. , Salzberg, Bruce, Silvers, David, Monroe, Paul S., Pandak, William M. , Anderson, Frank , Valentine, John F. , Wild, Gary , Geenen, Daniel J., Sprague, Rebecca , Targan, Stephan R. , Rutgeerts, P., Vexler, Vladimir, Young, David M., Shames, Richard

Mayo Clinic

Gut | April 7, 2006 | Volume: 55 | Issue: 11 | Pages: 1568-1574

10.1136/gut.2005.089854 | PMID 16603634 Get It

Background: An uncontrolled pilot study demonstrated that daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), might be effective for the treatment of active ulcerative colitis. Methods: A randomised, double blind, placebo controlled trial was conducted to evaluate the efficacy of daclizumab induction therapy in patients with active ulcerative colitis. A total of 159 patients with moderate ulcerative colitis were randomised to receive induction therapy with daclizumab 1 mg/kg intravenously at weeks 0 and 4, or 2 mg/kg intravenously at weeks 0, 2, 4, and 6, or placebo. The primary end point was induction of remission at week 8. Remission was defined as a Mayo score of 0 on both endoscopy and rectal bleeding components and a score of 0 or 1 on stool frequency and physician’s global assessment components. Response was defined as a decrease from baseline in the Mayo score of at least 3 points. Results: Two per cent of patients receiving daclizumab 1 mg/kg (p = 0.11 v placebo) and 7% of patients receiving 2 mg/kg (p = 0.73) were in remission at week 8, compared with 10% of those who received placebo. Response occurred at week 8 in 25% of patients receiving daclizumab 1 mg/kg (p = 0.04) and in 33% of patients receiving 2 mg/kg (p = 0.30) versus 44% of those receiving placebo. Daclizumab was well tolerated. The most frequently reported adverse events in daclizumab treated patients compared with placebo treated patients were nasopharyngitis (14.6%) and pyrexia (10.7%). Conclusion: Patients with moderate ulcerative colitis who are treated with daclizumab are not more likely to be in remission or response at eight weeks than patients treated with placebo.